Company Filing History:
2 out of 46 
2 out of 3,222 
Years Active: 2010-2012
Title: Susan Desmond-Hellmann: Innovator in Cancer Treatment
Introduction
Susan Desmond-Hellmann is a prominent inventor based in Alamo, CA (US). She has made significant contributions to the field of oncology, particularly in the treatment of chronic lymphocytic leukemia (CLL). With a total of 2 patents, her work has had a profound impact on cancer therapies.
Latest Patents
Her latest patents include innovative treatments for chronic lymphocytic leukemia using anti-CD20 antibodies. The first patent focuses on the treatment of CLL with antibodies directed against the CD20 antigen. The second patent addresses hematologic malignancies associated with circulating tumor cells using a chimeric anti-CD20 antibody. These advancements represent a significant step forward in cancer treatment.
Career Highlights
Throughout her career, Susan has worked with leading companies in the biotechnology sector, including Biogen Idec, Inc. and Genentech, Inc. Her expertise and leadership have been instrumental in advancing cancer research and treatment options.
Collaborations
Susan has collaborated with notable professionals in her field, including Christine A. White and John G. Curd. These partnerships have further enhanced her contributions to cancer research and therapy development.
Conclusion
Susan Desmond-Hellmann is a trailblazer in the field of cancer treatment, with her innovative patents and collaborations paving the way for future advancements. Her work continues to inspire and impact the lives of many affected by cancer.